<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<?properties manuscript?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-journal-id">101182328</journal-id>
<journal-id journal-id-type="pubmed-jr-id">31840</journal-id>
<journal-id journal-id-type="nlm-ta">Expert Rev Cardiovasc Ther</journal-id>
<journal-id journal-id-type="iso-abbrev">Expert Rev Cardiovasc Ther</journal-id>
<journal-title-group>
<journal-title>Expert review of cardiovascular therapy</journal-title>
</journal-title-group>
<issn pub-type="ppub">1477-9072</issn>
<issn pub-type="epub">1744-8344</issn>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">29257730</article-id>
<article-id pub-id-type="pmc">6064643</article-id>
<article-id pub-id-type="doi">10.1080/14779072.2018.1418664</article-id>
<article-id pub-id-type="manuscript">NIHMS1500813</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Spectrin-based pathways underlying electrical and mechanical dysfunction in cardiac disease</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Hund</surname>
<given-names>Thomas J.</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="aff" rid="A2">2</xref>
<xref ref-type="aff" rid="A3">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Unudurthi</surname>
<given-names>Sathya D.</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="aff" rid="A2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Greer-Short</surname>
<given-names>Amara</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="aff" rid="A2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Patel</surname>
<given-names>Nehal</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="aff" rid="A2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Nassal</surname>
<given-names>Drew</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="aff" rid="A2">2</xref>
</contrib>
</contrib-group>
<aff id="A1">
<label>1</label>The Dorothy M. Davis Heart and Lung Research Institute, The Ohio State University Wexner Medical Center, The Ohio State University, Columbus OH 43210</aff>
<aff id="A2">
<label>2</label>Department of Biomedical Engineering, College of Engineering, The Ohio State University, Columbus OH 43210</aff>
<aff id="A3">
<label>3</label>Department of Internal Medicine, The Ohio State University Wexner Medical Center, The Ohio State University, Columbus OH 43210</aff>
<author-notes>
<corresp id="FN1"><bold>Corresponding author:</bold> Thomas J. Hund, Ph.D., <email>Thomas.Hund@osumc.edu</email>, The Dorothy M. Davis Heart and Lung Research Institute – Graves Hall, The Ohio State University Wexner Medical Center, 333 W. 10<sup>th</sup> Avenue, Columbus, OH 43210, P: 614 292-0755; F: 614 247-7799</corresp>
<fn fn-type="COI-statement" id="FN2">
<p id="P19">
<bold>Declaration of Interest</bold>
</p>
<p id="P20">The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. Peer reviewers on this manuscript have no relevant financial or other relationships to disclose.</p>
</fn>
</author-notes>
<pub-date pub-type="nihms-submitted">
<day>25</day>
<month>7</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="epub">
<day>26</day>
<month>12</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="ppub">
<month>1</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>29</day>
<month>7</month>
<year>2018</year>
</pub-date>
<volume>16</volume>
<issue>1</issue>
<fpage>59</fpage>
<lpage>65</lpage>
<!--elocation-id from pubmed: 10.1080/14779072.2018.1418664-->
<abstract>
<sec id="S1">
<title>Introduction</title>
<p id="P1">In the heart, pathways that transduce extracellular environmental cues (e.g. mechanical force, inflammatory stress) into electrical and/or chemical signals at the cellular level are critical for the organ-level response to chronic biomechanical/neurohumoral stress. Specifically, a diverse array of membrane-bound receptors and stretch-activated proteins converge on a network of intracellular signaling cascades that control gene expression, protein translation, degradation and/or regulation. These cellular reprogramming events ultimately lead to changes in cell excitability, growth, proliferation, and/or survival.</p>
</sec>
<sec id="S2">
<title>Areas covered</title>
<p id="P2">The actin/spectrin cytoskeleton has emerged as having important roles in not only providing structural support for organelle function but also in serving as a signaling “super highway,” linking signaling events at/near the membrane to distal cellular domains (e.g. nucleus, mitochondria). Furthermore, recent work suggests that the integrity of the actin/spectrin cytoskeleton is critical for canonical signaling of pathways involved in cellular response to stress. This review discusses these emerging roles for spectrin and consider implications for heart function and disease.</p>
</sec>
<sec id="S3">
<title>Expert Commentary</title>
<p id="P3">Despite growth in our understanding of the broader roles for spectrins in cardiac myocytes and other metazoan cells, there remain important unanswered questions, the answers to which may point the way to new therapies for human cardiac disease patients.</p>
</sec>
</abstract>
<kwd-group>
<kwd>ankyrin</kwd>
<kwd>arrhythmia (mechanisms)</kwd>
<kwd>calmodulin dependent kinase II</kwd>
<kwd>heart failure</kwd>
<kwd>ion channels</kwd>
<kwd>spectrin</kwd>
</kwd-group>
</article-meta>
</front>
</article>
</pmc-articleset>